FibroBiologics

FBLG

市值 US$688萬

Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged Discs HOUSTON, Oct. 14, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that IP Australia has issued a Notice of Acceptance for Australian Patent Application No. 2024200985, titled "Cellular Blend for the Regeneration of Chondrocytes or Cartilage Type Cells.

New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today that it has filed a U.S. patent application covering a new cell-based technology designed to continuously produce peptides such as GLP-1, GIP and GLP-2 inside the body. Today, popular GLP-1 medicines used for weight loss and diabetes generally require patients to take regular weekly injections or daily pills.

Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration HOUSTON, Sept. 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has granted European Patent No.

FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript

HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of a private placement on September 15, 2026, with Hamid Khoja, Ph.D.

Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds HOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.

Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated Fibroblasts HOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.

FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foot ulcers (DFUs). The compant describes the investigational treatment as a topically applied allogeneic cell therapy that uses donor fibroblasts, a type of specialized connective tissue cell, to accelerate wound healing.

HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the third batch of its CYWC628 drug product and its shipment to Australia in support of the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured in accordance with current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling its release for clinical use.

HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") on August 25, 2026, informing the Company that it has regained compliance with the bid price requirement in Listing Rule 5550(a)(2). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "FBLG.